INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Show other versions (1)

Bibliographic Details
Main Authors:	K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	cyp2c19*2 acute coronary syndrome cyp3a4 pharmacogenetics clopidogrel p2y12-receptor blockers
Online Access:	https://www.rpcardio.online/jour/article/view/125

Similar Items

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: K. B. Mirzaev, et al.
Published: (2018-03-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
by: Daniele Jones, et al.
Published: (2024-01-01)

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review
by: Rahel Tekeste, et al.
Published: (2022-04-01)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
by: Ahmed Shawky, et al.
Published: (2023-05-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Impact of CYP2C19 variants on clinical efficacy of clopidogrel and one-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention
by: Hong Sun, et al.
Published: (2016-11-01)

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
by: Mirzaev KB, et al.
Published: (2017-04-01)

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
by: R. Rahmatini, et al.
Published: (2018-04-01)

A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients
by: Hind Hassani Idrissi, et al.
Published: (2018-01-01)

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance
by: Usman Nawaz, et al.
Published: (2023-11-01)

Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam
by: Pablo Zubiaur, et al.
Published: (2022-11-01)

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01)

Efficacy and safety of antipsychotics in adolescents with an acute psychotic episode in relation to the activity of CYP3A and CYP2D6 isoenzymes
by: D. V. Ivashchenko, et al.
Published: (2020-12-01)

Influence of CYP2C19*2 gene variant on therapeutic response during clopidogrel treatment in patients with carotid artery stenosis
by: Bačković Dragana, et al.
Published: (2016-01-01)

The polymorphism of cytochrome P450 CYP2C19 and resistance to clopidogrel.
by: C. Simoglou
Published: (2017-03-01)

Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
by: J. E. Zhang, et al.
Published: (2017-05-01)

CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel
by: Yu-Wei Chen, et al.
Published: (2022-08-01)

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
by: Gower MN, et al.
Published: (2020-07-01)

GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA
by: K. B. Mirzaev, et al.
Published: (2015-10-01)

CYP2C19 gene polymorphism and its impact on the long-term prognosis after myocardial infarction
by: Mariya V. Solodun, et al.
Published: (2022-07-01)

Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
by: Sabina Semiz, et al.
Published: (2010-11-01)

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
by: Yujing Cheng, et al.
Published: (2023-01-01)

CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel
by: Ramazan Sabırlı, et al.
Published: (2021-03-01)

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis
by: Abdullah N. Alkattan, et al.
Published: (2022-06-01)

Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy
by: Yawei Yang, et al.
Published: (2020-06-01)

Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response
by: Kavita K. Shalia, et al.
Published: (2013-03-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease
by: Sudhir S. Shetkar, et al.
Published: (2014-01-01)

Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)
by: Renan Sukmawan, et al.
Published: (2021-04-01)

The correlation between CYP2C19 Polymorphisms and recurrent risk in Patients with Ischemic Stroke treated with Clopidogrel in Kurdistan region-Iraq
by: Hind Salim Jardaq, et al.
Published: (2022-12-01)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
by: Sherry-Ann Brown, et al.
Published: (2018-01-01)

Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses
by: Giada Scantamburlo, et al.
Published: (2023-10-01)

Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel
by: Nestorovska KA, et al.
Published: (2024-03-01)

Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province
by: Xiao-wen Yuan, et al.
Published: (2022-12-01)

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals
by: Anshu Kumar Yadav, et al.
Published: (2023-09-01)